The adenovirus E1A protein has been shown to be involved in the potentiation of apoptosis induced by chemotherapeutic agents, yet the molecular events of E1A-mediated apoptosis are not very clear. A recent report has suggested that deamidation of the Bcl-X L protein inhibits its antiapoptotic ability and leads to apoptosis induced by alkylating agents in Rb-deficient tumor cells. Since Rb is known to interact with E1A, which interrupts Rb's normal function, we examined Bcl-X L deamidation and cell death induced by cisplatin in E1A transfectants. We found that the E1A transfectants became sensitive to cisplatininduced apoptosis compared to the parental cells, SKOV3.ip1. Our data show that cisplatin treatment induced the modification of Bcl-X L in the E1A transfectants in dosage and time-dependent manner. Furthermore, phosphatase treatment had no effect on the level of Bcl-X L modification, whereas alkaline lysis buffer appeared to induce the same modification of Bcl-X L . Ectopic expression of the deamidated forms of Bcl-X L in SKOV3.ip1 cells revealed that the modification to the Bcl-X L protein molecules was deamidation. Expression of the E1A mutant (dl1108) which contains deletion at CR2 domain suppressed Bcl-X L deamidation and apoptosis induced by cisplatin. We also found that expression of the nondeamidated Bcl-X L protected E1A transfectants from apoptosis. These findings suggest that Bcl-X L deamidation contributes to E1A-mediated cisplatin sensitization in SKOV3.ip1 cells.
Introduction
The adenovirus E1A protein was considered originally to be an oncoprotein, but later it has been demonstrated that E1A has tumor suppressor activity (Frisch and Mymryk, 2002) . E1A also has been reported to increase cellular susceptibility to apoptosis induced by various stimuli (White, 2001 ). Although the mechanisms by which E1A-mediated apoptosis occurs are not very clear, some pathways of E1A-mediated sensitization have been reported and include nuclear factor-kB (NFkB) inactivation following treatment with ionization radiation (Shao et al., 1997) or gemcitabine (Lee et al., 2003) , downregulation of the Her-2/neu expression in response to paclitaxel treatment (Uneo et al., 1997) , activation of the caspase-3 pathway (Uneo et al., 2000) , inactivation of CDK inhibitor p21 in DNA-damaged cells (Chattopadhtyay et al., 2001) , and inhibition of the PI3K/Akt pathway to cisplatin (Viniegra et al., 2002) or serum deprivation (Lee et al., 2002) . In addition, some suggest that E1A sensitization to an anticancer drug requires at least two pathways, activation of proapoptotic factors and suppression of apoptotic inhibitors (Duelli and Lazebnik, 2000) .
E1A protein is known to form a complex with the tumor suppressor Rb and to inactivate Rb function (Whyte et al., 1988; Nevins, 1992) . The interaction of E1A with the Rb disrupts the Rb-E2F complex and frees E2F resulting in stimulation of E2F-dependent transcription (Chau and Wang, 2003) . E1A binds to Rb, primarily through a motif that is located in conserved region 2 (CR2) (Frisch and Mymryk, 2002) . Interestingly, an E1A mutant lacking this motif no longer promotes chemosensitivity in human and mouse fibroblasts (Samuelson and Lowe, 1997) or sensitizes a mouse melanoma cell line to stresses (Deng et al., 2002) .
Recently, it has been demonstrated that when tumor cells lacking Rb were treated with DNA-damaging agents such as cisplatin, it causes deamidation of the protein Bcl-X L (Deverman et al., 2002) , an antiapoptotic member of the Bcl-2 family. This Bcl-X L protein modification inhibits its antiapoptotic ability and leads to tumor cells apoptosis. This deamidation modification is suppressed when the activated (hypophosphorylated) form of Rb is present (Deverman et al., 2002) . Recently, the potential role of Bcl-X L deamidation related to tumor formation has been observed in human hepatocellular carcinomas (HCC) where the level of deamidated Bcl-X L is lower than in normal liver tissue (Takehara and Takahashi, 2003) .
This new role of Rb in regulation of modification of Bcl-X L has prompted us to test the hypothesis that interaction of the activated form of Rb with E1A may trigger signals, which induce deamidation of Bcl-X L in response to DNA damage, and this results in decreasing cell survival. To test this hypothesis, we used the human ovarian carcinoma cell line SKOV3.ip1, which exhibits normal levels of Rb and an E1A transfectant SKO-V3.ip1-E1A cell line (Yu et al., 1993; Shao et al., 1997) , and examined the contribution of E1A to the induction of Bcl-X L modification and cell death by cisplatin. Our results reveal that cisplatin induces the slowly migrating Bcl-X L protein in the E1A transfectants but not to any significant degree in the parental cells. Furthermore, the modification of Bcl-X L is not due to phosphorylation of Bcl-X L , but the protein shows the characteristic of slowly migrating form of deamidated Bcl-X L . We also showed that expression of E1A mutant lacking Rbbinding domain suppresses Bcl-X L deamidation. The present study provides another molecular pathway for the E1A-mediated sensitization of cisplatin-induced apoptosis.
Results

E1A sensitizes ovarian cancer cells to cisplatin
To test whether E1A can sensitize human ovarian cancer cells to a DNA-damaging agent such as cisplatin, we treated a human ovarian cancer cell line derivative, SKOV3.ip1, and a stably transfected wild-type Ad5 E1A cell line, SKOV3.ip1-E1A, with 1-10 mM of cisplatin for 12-48 h. Following 10 mM cisplatin treatment for 48 h, the E1A transfectants showed typical apoptotic phenomena in a DNA fragmentation assay (Figure 1a and b). This DNA fragmentation was less apparent in the parental cells (SKOV3.ip1).
Rb maintains normal status in ovarian cancer cells
A recent study has shown that DNA-damaging agents induce deamidation of the antiapoptotic protein Bcl-X L in Rb-deficiency tumor cells. This Bcl-X L deamidation results in a sensitization of the tumor cells to DNAdamaging agents (Deverman et al., 2002) . To investigate whether the E1A sensitization of ovarian cancer cells is through interference with the functioning of Rb, we set up an assay to examine the Rb status of SKOV3.ip1 cell. We first established a functional assay for detecting Rb status using HeLa cells as a positive control (Chellappan et al., 1992) . Following serum starvation for 24 h, predominantly hypophosphorylated Rb forms were revealed by Western blotting with antibodies to pRb and ppRb. After serum stimulation, the hyperphosphorylated form of Rb increased in proportion to the stimulation time from 6 to 48 h (Figure 2a ). We then examined the Rb status in both SKOV3.ip1 and SKOV3.ip1-E1A cells. Hypophosphorylated Rb (pRb) was revealed under serum starvation conditions (Figure 2b ), whereas hyperphosphorylated forms of Rb (ppRb) appeared much more in SKOV3.ip1 than in SKOV3.ip1-E1A cells after serum stimulation for 24 h. This suggests that the E1A-associated Rb complex interfered with Rb phosphorylation. To determine the interaction between Rb and E1A, we immunopreciptated the cell lysates from SKOV3.ip1 and SKOV3.ip1-E1A cells with an anti-E1A antibody followed by immunoblotted for pRb. As shown in Figure 2c , Rb was immunoprecipitated with E1A in the cell extracts from SKOV3.ip1-E1A cells, either untreated or treated with cisplatin. In contrast, no Rb protein was immunoprecipitated in cell extract from SKOV3.ip1 cells. The association of Rb with E1A and Rb phosphorylation by serum stimulation provide evidence that Rb is in a normal state (Scheffner et al., 1991) .
Modification of Bcl-X L correlates with E1A-mediated sensitization to cisplatin To determinate whether modification of Bcl-X L could be another mechanism for E1A-mediated apoptosis by cisplatin in the SKOV3.ip1-E1A cells, we assayed protein expression of E1A, Bcl-X L , and Bcl-2. Western blots analysis revealed that cisplatin induced the appearance of slow-migrating Bcl-X L bands in a dosedependent fashion, whereas Bcl-2 appeared to be unaffected by cisplatin treatment. The ratio of the intensity of slow-migrating Bcl-X L bands to the fastmigrating Bcl-X L bands, represented as a percent modification of Bcl-X L , increased as the dosage in- (Figure 3a ). This ratio remained relatively unchanged in SKOV3.ip1 cells regardless of the amount of cisplatin applied. When 10 mM of cisplatin were applied for 0, 24, 48, and 72 h, the percent modification of Bcl-X L was 14.8, 26, 57.9, and 69.6%, respectively. In contrast, the percent modified of Bcl-X L had changed only slightly at 72 h in parental cells (Figure 3a) . Furthermore, the modification form of the Bcl-X L correlated temporally with cisplatin-induced cell death Figure 2 Rb is normal in HeLa and SKOV3.ip1 cells and E1A interacts with Rb in SKOV3.ip1 cells. (a) HeLa cells were serumstarved for 24 h followed by serum stimulation for the indicated time before harvesting. SFM represents serum-free medium. A plus sign indicates cells treated with serum-free medium for 24 h. A minus sign indicates cells treated with normal serum medium. Cell lysates were prepared and analysed as described under 'Materials and methods'. Protein lysates (50 ml) were subjected to Western blotting with antibodies against pRb, ppRb, and finally a-tubulin as an internal control. (b) SKOV3.ip1 and SKOV3.ip1-E1A cells were serum-starved for 24 h and then serum stimulation for 24 h. Cell lysates were subjected to Western blotting. (c) Equal numbers of cells were treated with or without cisplatin for 48 h and wholecell lysates were immunoprecipitated with anti-E1A antibody prior to Western blotting with anti-Rb antibody. SKOV3.ip1 was served as negative control. IgG represents immunoglobulin G heavy chain. Figure 3 Cisplatin inducing Bcl-X L modification and cell death is dose and time dependent in E1A transfectants. (a) Top, cells were incubated with cisplatin at the indicated concentrations for 48 h. Cell viability was assessed by the MTS assay and the values are presented as means (n ¼ 3). Bottom, cell lysates were prepared as described in 'Materials and methods' and protein levels were determined by Western blot analysis using antibodies for E1A, Bcl-X L , Bcl-2, and finally a-tubulin as an internal control. The percent Bcl-X L modification is represented as a ratio of the intensity of the slow-migrating form of Bcl-X L to the intensity of the slow and fastmigrating form of Bcl-X L . (b) Top, cells were incubated with cisplatin for 24, 48, 72 h. Cell viability was assessed by MTS assay and the values presented are mean (n ¼ 3). Bottom, cell lysates were subjected to Western blot analysis.
in E1A transfectants ( Figure 3b ). From these findings, we suggest that modification of Bcl-X L is involved in E1A sensitization of ovarian cancer cells to cisplatin.
Cisplatin induces cytochrome c release and caspase-3 activation in SKOV3.ip1-E1A cells Loss of Rb leads to release of cytochrome c from mitochondria, and this activates APAF-1, caspase-9, and caspase-3, which promote apoptosis (Chau and Wang, 2003) . On the other hand, Bcl-X L can block cytochrome c release from mitochondria and prevent apoptosis. To determine whether E1A sensitization of ovarian cancer cells to cisplatin occurs through cytochrome c release induced by inactivated Rb and modification of Bcl-X L , we examined cytochrome c levels using cytosolic extracts of the cisplatin-treated SKOV3.ip1 and SKOV3.ip1-E1A cells. Our results showed that the cytochrome c levels increased as the length of the cisplatin treatment increased from 0 to 48 h in the SKOV3.ip1-E1A cells, whereas cytochrome c was barely detectable in the SKOV3.ip1 cells ( Figure 4a ). To identify whether cisplatin-induced cytochrome c release could activate caspase-3, we further examined caspase-3 cleavage in the cisplatin-treated cells by Western blot analysis. The cleaved form of caspase-3 was detected in the cisplatin-treated SKOV3.ip1-E1A cells at 24 and 48 h, but not in the SKOV3.ip1 cells (Figure 4b ). From these finding, we have confirmed that cytochrome c release and caspase-3 activation were involved in E1A-mediated sensitization to cisplatin in SKOV3.ip1 cells.
Bcl-xL modification is not by phosphorylation
To determine whether or not the cisplatin-induced modification of Bcl-X L is phosphorylation, cell extracts were treated with l-phosphatase prior to immunoblots. We first examined the hyperphosphorylated form of Rb in serum-stimulated cell extracts derived from HeLa and SKOV3.ip1 cells. As expected, ppRb bands were abolished after phosphatase treatment ( Figure 5a ).
When cellular extract from paclitaxel-treated cells were incubated with phosphatase, the slowest migrating band, a characteristic phosphorylated form of Bcl-X L induced by paclitaxel (Poruchynsky et al., 1998; Deverman et al., 2002) , was diminished ( Figure 5b ). In contrast, the percent modification of Bcl-X L in cisplatintreated SKOV3.ip1-E1A cells remained relatively unchanged in the absence or presence of phosphatase treatment ( Figure 5c ). In summary, we have demonstrated that the cisplatin-induced modification of Bcl-X L in SKOV3.ip1-E1A cells is not due to phosphorylation.
In vitro alkaline treatment induces Bcl-X L modification, which migrates in the same position as the deamidated forms of Bcl-X L Alkaline conditions are known to increase the rate of protein deamidation (Robinson and Robinson, 2001; Robinson, 2002) . To examine whether alkaline condition could affect Bcl-X L modification, we treated the cells with alkaline lysis buffer (pH 10) under various conditions. The alkaline treatment for 6 or 16 h at 371C appeared to convert the fast-migrating protein of Bcl-X L 
to slow-migrating protein (Figure 6a ). In contrast, no induction of the slow-migrating protein of Bcl-X L from fast-migrating protein was revealed in the cells lysed with a neutral buffer (pH 7.4). Moreover, we did sitedirected mutagenesis of Bcl-X L at two potential deamidation sites (asparagines 52, 66) as described previously (Deverman et al., 2002) . Ectopic expression of the Bcl-X L constructs in SKOV3-ip1 cells were tested for Bcl-X L modifications. In the constructs N52A, N66A, and N52/66A, where alanines were substituted for asparagines, we detected a decreased level of slowmigrating Bcl-X L protein compared to wild-type or endogenous Bcl-X L (Figure 6b ). In the construct N66D where aspartate was substituted for asparagines 66, we detected increased level of the slow-migrating Bcl-X L protein. This single deamidated form migrated in the same position as the slow-migrating Bcl-X L protein generated from wild-type transfected or endogenous Bcl-X L protein. Moreover, when both asparagines 52 and 66 were replaced by aspartates, N52/66D, the slowest migrating form of Bcl-X L protein was detected. This result suggested that formation of the slowmigrating bands is due to deamidation of the Bcl-X L protein.
Olomoucine suppresses Bcl-X L deamidation and renders SKOV3ip1-E1A cells resistant to cisplatin It has been shown that olomoucine, a cyclin-dependent kinase (CDK) inhibitor, can suppress Bcl-X L deamidation and render p53-null MEFs resistant to cisplatininduced apoptosis (Abraham et al., 1995; Deverman et al., 2002) . In principle, this CDK inhibitor can block Rb phosphorylation and thus inhibit deamidation of Bcl-X L . To test whether olomoucine could suppress Bcl-X L deamidation in SKOV3ip1-E1A cells, we examined cisplatin-induced Bcl-X L deamidation after olomoucine treatment. Western blot assay demonstrated that the percent Bcl-X L deamidation in both untreated and olomoucine-treated cells remained low compared to cisplatin-treated cells. The high level of Bcl-X L deamidation in cisplatin-treated cells was suppressed when the cells was pretreated with olomoucine ( Figure 7a ). This reduced level of Bcl-X L deamidation was accompanied by increased cell survival, and olomoucin-treated SKOV3ip1-E1A cells were as resistant to cisplatininduced cell death as SKOV3ip1 cells (Figure 7b ). 
suppresses Bcl-X L deamidation and apoptosis induced by cisplatin E1A is known to interact with the Rb protein to release E2F. To show that loss of Rb function is required for E1A to sensitize cells to cisplatin, we first examined whether E1A-mediated E2F activation is affected by E1A mutant, dI1118. The dI1118 has a deletion at CR2 domain which abrogates its binding with Rb (Frisch and Mymryk, 2002) . E1A or dI1118 along with E2F-Luc were transiently cotransfected into SKOV.ip1 cells. By measuring E2F-Luc reporter activity, E1A-mediated E2F activation, which indicates Rb inactivation, was determined. In these experiments, we have calculated luciferase activity relative to vector control which was set at 100%. In the transfected cell lines examined, the dI1118 was unable to activate the E2F-Luc reporter, whereas E1A showed near fivefolds increase in activity ( Figure 8a ). Next, we analysed the viability of these transfected cells to cisplatin. E1A-transfected cells showed about 40% of viability to cisplatin, whereas, dI1118 and vector were resistant to such treatment (Figure 8b ). This result is in agreement with the previous finding that the CR2 domain is required for E1A-mediated apoptosis (Samuelson and Lowe, 1997; Deng et al., 2002) . Immunoblot analysis revealed that E1A proteins were expressed in both E1A-and dI1118-transfected cells (Figure 8c ). The variable migration patterns are due to phosphorylation and post-translational modification of E1A (Samuelson and Lowe, 1997) . When Bcl-X L deamidation was examined, cisplatin appeared to induce deamidation of Bcl-X L in the E1A-transfected cells, and the percent deamidation of Bcl-X L increased from 33.2 to 55.9%. In contrast, cisplatin had a minor effect on deamidation of Bcl-X L in the dI1118-transfected cells (Figure 8c) , suggesting that the CR2 domain of E1A is required for Bcl-X L deamidation in SKOV3.ip1 cells.
The nondeamidated Bcl-X L (N52/66A) transfectants are resistant to cisplatin To determine whether expression of nondeamidated form of Bcl-X L could protect the SKOV3.ip1/E1A cells from cell death, cells were transiently transfected with the different forms of Bcl-X L as indicated (Figure 9a ). Immunoblot analysis showed the expected patterns of Bcl-X L deamidation induced by cisplatin in the vector, WT, and N52/66D-transfected cells, respectively. Conversely, cisplatin-induced Bcl-X L deamidation was suppressed in N52/66A-transfected cells (Figure 9a ). Our data show that the Bcl-X L (N52/66D)-transfected cells increased apoptotic activity 2-3-folds than that of wild-type Bcl-X L (Figure 9b ). Whereas Bcl-X L (N52/ 66D) displayed strong proapoptotic activities in the absence or presence of cisplatin, we found that nondeamidated Bcl-X L (N52/66A) protected E1A transfectants from cisplatin-induced cell death. As shown in Figure 9b , the level of apoptosis induced by cisplatin in SKOV3-ip1/E1A cells expressing nondeamidated Bcl-X L (N52/66A) was significantly lower than those cells expressing wild-type Bcl-X L (Po0.05). This is consistent with previous finding (Deverman et al, 2002 ) that Bcl-X L (N52/66A) blocked deamidation and increased the antiapoptotic activity of Bcl-X L . These results suggest that deamidated Bcl-X L may play a direct role in proapoptosis.
Discussion
A recent study has suggested that deamidation of Bcl-X L protein inhibits its antiapoptotic ability and E1A-mediated Bcl-X L deamidation C-Y Chang et al leads to apoptosis induced by alkylating agents in Rbdeficient tumor cells. Furthermore, this Bcl-X L modification occurs at asparagines 52 and 66 and is suppressed when the activated form of Rb is present (Deverman et al., 2002) . We examined whether deamidation of Bcl-X L could be induced by cisplatin in the E1A transfectants. The results indicate that E1A interacts mainly with activated form of Rb in SKO-V3.ip1 ovarian cancer cells, and this interaction is sufficient to abrogate Rb's function and induce modification of Bcl-X L in the presence of cisplatin. This Rb connection to modification of Bcl-X L is further strengthened in the dI1118-transfected cells, where a deletion at Rb-binding domain (CR2) in dI1118 suppresses the modification of Bcl-X L to cisplatin treatment. This result suggests that the CR2 domain of E1A is required for Bcl-X L deamidation in SKOV3.ip1 cells. Furthermore, the cisplatin-induced modified form of Bcl-X L coincides with activation of a downstream apoptotic pathway including cytochrome c release into cytoplasm and cleavage of procaspase-3. This Bcl-X L modification is presumably due to deamidation, which alters its antiapoptotic activity in E1A-expressing cells in the presence of cisplatin. However, unlike a retraction of original paper (Deverman et al., 2003) that stated antiapoptotic activity of deamidated Bcl-X L (N52/ 66D) was similar to that of wild-type Bcl-X L , we showed that Bcl-X L (N52/66D) increased apoptotic activity 2-3-folds than that of wild-type Bcl-X L . Our data appear to support the notion that E1A sensitization to the anticancer drug requires at least two pathways, activation of proapoptotic factors and inactivation of antiapoptotic factors (Duelli and Lazebnik, 2000) . It is important to note that the other effects of E1A expression such as inactivation of NF-kB (Shao et al., 1997) , CDK inhibitor p21 (Chattopadhtyay et al., 2001) , and inhibition of the PI3K/Akt pathway also contribute to cell death. On the other hand, E1A alone did not induce Bcl-X L deamidation, or stimulate cell death in SKOV3.ip1 cells. Consistent with previous finding (Deverman et al., 2002) , our results indicate Rb inactivation and DNA-damaging agents are required for inducing Bcl-X L deamidation in SKOV3.ip1 cells.
Our data show moderate levels of Bcl-X L deamidation and apoptosis induced by cisplatin in E1A transfectants as compared to a previous study of Rbdeficient cancer cells (Deverman et al., 2002) . This might be explained by the fact that a fraction of the activated form of Rb was not completely abrogated by E1A as evidenced by the Rb functional assay in E1A transfectants, which resulted in partial suppression of Bcl-X L deamidation mediated by the active form of Rb. In addition, a relatively moderate level of Bcl-X L protein is present in SKOV-3 cells (Amundson et al., 2000) , the parental cells of SKOV3.ip1, which may also contribute to the moderate level of Bcl-X L deamidation and cell death induced by cisplatin. Since there is a strong correlation between Bcl-X L protein levels and the sensitivity to cytotoxic agents in the 60 cell lines of the National Cancer Institute's Anticancer drug screen (NCI-ADS) (Amundson et al., 2000) , inactivation of Bcl-X L , even at moderate level, may be sufficient to induce 40-60% cell death by cisplatin in E1A transfectants. Platinum-induced DNA damage activates p53 pathways, which lead to cell death, and also contribute to the cytotoxicity of cisplatin (Agarwal and Kaye, 2003) . Furthermore, apoptosis through Rb loss, either by E1A or in Rb knockout mice, is substantially p53 dependent (White, 1996) . Since SKOV3.ip1 cells do not express p53 protein, the induction of apoptosis by cisplatin is not through a p53-dependent pathway (Brader et al., 1997) .
E1A normally binds to the hypophosphorylated form of Rb that disrupts the interaction between Rb and E2F, yet some portion of Rb molecules might be in a hyperphosphorylated form activated by CDK complexes even in the presence of E1A. In fact, it has been demonstrated that E1A can induce phosphorylation of Rb independently of association between E1A and Rb in normal quiescent cells (Wang et al., 1991) . We observed that when the cells were treated with olomoucine, an inhibitor of CDKs, both cisplatin-induced cell death and Bcl-X L deamidation were reduced. The formation of the hyperphosphorylated form of Rb is blocked by olomoucine and some Rb molecules could remain in an active form, which would suppress Bcl-X L modification induced by cisplatin. Interestingly, the Bcl-X L migration pattern induced by taxol, which results in phosphorylation of Bcl-X L (Poruchynsky et al., 1998; Deverman et al., 2002) , are different from Figure 9 Ectopic expression of the nondeamidated Bcl-X L (N52/ 66A) protects the cells from cisplatin-induced apoptosis. SKO-V3.ip1-E1A cells were transiently transfected with plasmids as indicated, followed by cisplatin treatment for 36 h. (a) Levels of Bcl-X L expression and deamidation ratio were assessed by Western blot analysis. (b) The dead cells were examined by trypan blue exclusion assay. The values presented are mean (n ¼ 3). The nondeamidated Bcl-X L (N52/66A) transfected cells were resistant to cisplatin-induced apoptosis, whereas the cells expressed constitutively deamidated Bcl-X L (N52/66D) enhanced cell death. *Po0.05 for Bcl-X L (N52/66A) and WT. **Po0.001 for Bcl-X L (N52/66D) and WT (t-test).
Bcl-X L deamidation induced by cisplatin in E1A transfectants. The signal pathways that lead to this difference are not clear and need to be subjected to further study. Protein modification through nonenzymatic deamidation of glutamine and asparagine residues has been proposed to serve as a molecular timer for biological events such as protein turnover, development, and aging (Robinson and Robinson, 2001; Robinson, 2002) . The first strong evidence that protein deamidation regulates a cellular response was demonstrated in a study of deamidation in the antiapoptotic protein Bcl-X L induced by DNA-damaging agents (Deverman et al., 2002) . This Bcl-X L deamidation is related to cell death by apoptosis and this is further supported by a recent finding showing that Bcl-X L deamidation is suppressed in HCC, but remains active in normal or adjacent nontumor liver tissues (Takehara and Takahashi, 2003) . Apparently, Bcl-X L deamidation in normal liver cells is not directly dependent on Rb's status and DNA damage. This study suggests that suppression of Bcl-X L deamidation may play an important role when malignant tumors acquire resistance to cell death. Recent studies of oncogenic tyrosine kinase-induced resistance to apoptosis also suggest that inhibition of Bcl-X L deamidation may be critical in T-cell transformation (Zhao et al., 2004) . In addition, this inhibition of Bcl-X L deamidation observed in thymocytes is not regulated by Rb expression or activation. From these findings, Rb-regulated Bcl-X L deamidation is probably cell-type dependent. However, it is unclear at the present time how Bcl-X L deamidation is regulated in normal or cancer cells and whether deamidation reaction is mediated by specific regulators or by other nonenzymatic reactions. In summary, the present study provide further evidence for Rb inactivation and DNA-damaging agent induce deamidation of Bcl-X L and it also suggests that Bcl-X L deamidation provides another molecular pathway for E1A-mediated sensitization of cisplatin-induced cell death.
Materials and methods
Cell lines and plasmids
To assess the effect of E1A on sensitivity to cisplatin, the SKOV3.ip1 and SKOV3.ip1-E1A human ovarian carcinoma cell lines (kindly provided by Dr MC Hung, University of Texas MD Anderson Cancer Center, Houston, TX, USA) were used (Yu et al., 1993; Shao et al., 1997) . The cells were cultured in Dulbecco's modified Eagle's medium/F12 (Life Technologies) supplemented with 10% fetal calf serum and 1% penicillin/streptomycin. The SKOV3ip1-E1A cells were grown with the addition of G418 (400 mg/ml) (Life Technologies). E1A and E1A mutant dl1108 were also obtained from Dr MC Hung. dl1108 containing a deletion at CR2 domain (pRb-binding) was described previously (Shisler et al., 1996; Samuelson and Lowe, 1997) . Both DNA were recloned into pCMV-promoted vectors. E2F-luciferase reporter was purchased from CLONTECH, and b-galactosidase vector was purchased from Promega. All plasmid DNA used for transfection was isolated by using QIAGEN s Plasmid Midi kit.
Cell viability assay
Cells were seeded into triplicate wells at 4 Â 10 3 cells/well in 96-well plates overnight before exposure to 1-10 mM of cisplatin for the indicated time. Then, the MTS cytotoxicity assay (CellTiter 96 AQ ueous One Solution Cell Proliferation Assay, Promega) was performed according to the manufacture's instructions. Briefly, the medium was removed and replaced with 100 ml of medium and 20 ml of MTS solution, and the cells were incubated for 1-4 h at 371C until the solution color changed from yellow to blue. Absorbance was determined on a plate reader at 490 nm.
DNA fragmentation assay
Approximately 5 Â 10 5 cells were seeded and incubated overnight before exposure to 1-10 mM of cisplatin for the indicated time. Cells were collected and washed with PBS, then resuspended in 50 ml of TE buffer with the addition of 0.5 ml GE lysis buffer (Genomic Reagent Kit, Biolight) for 1-2 h at 371C. DNA was extracted with 0.5 ml of phenol/chloroform (24:1). After centrifugation, the aqueous phase was precipitated with equal volume of isopropanol. Precipitated DNA was analysed on a 2% agarose gel.
Immunoblotting
Approximately 2 Â 10 6 cells were harvested and lysed in lysis buffer containing 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP40, 10 mM phenylmethylsulfonyl fluoride, 10 mM aprotenin, and 10 mM leupeptin. For the alkaline pH experiment, the same lysis buffer was used except that 50 mM Tris-HCL, pH 10, was substituted and the proteins were incubated at 4 or 371C for 6 or 16 h. For the cytochrome c release experiments, cytosolic protein lysates were prepared from S-100 fraction according to the previous procedures (Dignam et al., 1983) . Immunoblot analysis was performed as described previously (Chen et al., 1995) . The proteins were separated on SDS/polyacrylamide gel, and transferred to immobilon-P membrane (Millipore). All primary antibodies were diluted 1:500 or 1:1000 in 1% nonfat milk-containing Tris-buffer saline and 0.1% tween-20 (TBST). The following antibodies were used: anti-E1A (M58) from NeoMarkers; antiBcl-X L (H-62), anti-Bcl-2 (100), and anticytochrome c antibody (H-104) from Santa Cruz; anticaspase-3 from Lab Vision; and anti-a-tubulin from Oncogene. The secondary antibody used was horseradish peroxidase IgG conjugate (Oncogene) and the bound protein was visualized by ECL reagent (Amersham). The optical densities of bands were analysed using ImageQuqNT software with a Personal Densitometer SI (Molecular Dynamic).
Coimmunoprecipitation
Approximately 2 Â 10 6 cells were harvested and lysed in lysis buffer containing 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP40, 10 mM phenylmethylsulfonyl fluoride, 10 mM aprotenin, and 10 mM leupeptin. Protein lysates (2 mg) were incubated with 4 mg anti-E1A antibody (M58) from NeoMarkers for 1 h at 41C followed by addition of 20 ml of protein A plus agarose beads (Oncogene) for 16 h at 41C. The immunocomplex was washed four times with the same lysis buffer, and the bound proteins were eluted by 5 Â SDS loading buffer at 1001C for 5 min and resolved by SDS-PAGE for immunoblotting analysis.
Effect of serum starvation on Rb phosphorylation 5 Â 10 5 cells of HeLa, SKOV3.ip1 and SKOV3.ip1-E1A were cultured in 10% FBS-supplemented medium overnight, which were washed with PBS twice and cultured in serum-free medium for 24 h. These cells were then exposed to 10% FBSsupplemented medium and the treated cells were collected at different time intervals. Protein lysate (50 mg) were subjected to Western blotting. The anti-pRb antibody (1F8) was from DBS and the anti-ppRb antibody (Ser 807/811) was from New England Biolabs.
Trypan blue exclusion assay 1 Â 10 5 cells were seeded overnight. Cells were then treated with 10 mM of cisplatin for 48 h, and both adherent and nonadherent cells were pooled and resuspended in 5 ml medium. Cells (10 ml) were mixed with 10 ml trypan blue solution for 3 min and the cells that failed to exclude blue dye were counted by hemocytometer. Cell viability was calculated as the number of cells that excluded the dye divided by the total number of the cells counted as a percentage.
In vitro phosphatase treatment Cells were treated with 10 mM of cisplatin or 0.1 mM of paclitaxel for 48 h (SKOV3.ip1-E1A cells), or 24 h of serum starvation (HeLa cells and SKOV3.ip1). Cell lysate (100 ml) was mixed with 10 Â phosphatase buffer and 2 mM MnCl 2 , and then incubated with 400 U of l-phosphatase (New England BioLabs) for 3 h at 301C. The samples were analysed by Western blotting.
cDNA cloning and site-directed mutagenesis of Bcl-X L Total RNA from human fibroblast was isolated using an RNeasy mini kit (Qiagen). Reverse transcription of the RNA was carried out with SuperScript II (Invitrogen). The cDNA products were PCR amplified by the primers 5 0 -TGC TCT AGA GCA TTG GAC AAT GGA CTG GTT GA and 5 0 -GCTCTA GAG CGT GAG TGG ATG GTC AGT G, designed according to the published Bcl-X L sequence (Strausberg et al., 2002) . The PCR product containing the coding region of Bcl-X L was subcloned in-frame into the XbaI site of pFLAG-CMV-2 (Sigma), and verified by DNA sequencing. Mutations were generated in pFLAG-CMV-2-Bcl-X L by converting the codons for asparagines 52 and 66 to alanine or aspartate (N52A, N66A, N52/66A, N66D, N52/ 66D) using the QuickChange Site-directed Mutagenesis System (Strategene). All mutations were confirmed by DNA sequencing. The original plasmid or mutant plasmids were transiently transfected into SKOV3.ip1 cells using Lipofectin reagent (Life Technologies). Total lysates were prepared 2 days after transfection and subjected to Western blotting analysis.
In vivo olomoucine treatment Cells were first preincubated with 50 mM of olomoucine (Sigma) for 24 h, and then treated with 1-10 mM of cisplatin for 48 h prior to harvest. For Western blotting, cell lysate was used. For cell viability, both adherent and nonadherent cells were pooled for a trypan blue exclusion assay.
Transfections
The wild-type or mutant Bcl-X L plasmids were transiently transfected into SKOV3.ip1 or SKOV3.ip1-E1A cells using Lipofectin reagent (Life Technologies). Total lysates were prepared 2 days after transfection and subjected to Western blotting analysis.
For luciferase assay, E1A or dI1118 were transiently cotransfected with E2F-Luc reporter and b-gal vector into SKOV3.ip1 cells. Cell extracts were prepared 2 days after transfection for assaying luciferase and b-galactosidase activities.
